 |
|
Invasive Pneumococcal Disease Caused by Nonvaccine Serotypes Among Alaska Native Children With High Levels of 7-Valent Pneumococcal Conjugate Vaccine Coverage
Rosalyn J. Singleton, MD, MPH;
Thomas W. Hennessy, MD, MPH;
Lisa R. Bulkow, MS;
Laura L. Hammitt, MD;
Tammy Zulz, BS;
Debby A. Hurlburt, RN;
Jay C. Butler, MD;
Karen Rudolph, PhD;
Alan Parkinson, PhD
JAMA. 2007;297:1784-1792.
Context With routine childhood vaccination using heptavalent pneumococcal conjugate vaccine, one concern has been the potential for emergence and expansion of replacement disease caused by serotypes not contained in the heptavalent conjugate vaccine.
Objective To determine whether replacement disease is associated with the overall decline in invasive pneumococcal disease among Alaska Native children.
Design, Setting, and Patients Alaska statewide longitudinal population-based laboratory surveillance of invasive Streptococcus pneumoniae infections from January 1, 1995, through December 31, 2006.
Main Outcome Measures Incidence and types of pneumococcal disease in children younger than 2 years.
Results In the first 3 years after introduction of routine vaccination with heptavalent pneumococcal conjugate vaccine, overall invasive pneumococcal disease decreased 67% in Alaska Native children younger than 2 years (from 403.2 per 100 000 in 1995-2000 to 134.3 per 100 000 per year in 2001-2003, P<.001). However, between 2001-2003 and 2004-2006, there was an 82% increase in invasive disease in Alaska Native children younger than 2 years to 244.6/100 000 (P = .02). Since 2004, the invasive pneumococcal disease rate caused by nonvaccine serotypes has increased 140% compared with the prevaccine period (from 95.1 per 100 000 in 1995-2000 to 228.6 in 2004-2006, P = .001). During the same period, there was a 96% decrease in heptavalent vaccine serotype disease. Serotype 19A accounted for 28.3% of invasive pneumococcal disease among Alaska children younger than 2 years during 2004-2006. There was no significant increase in nonvaccine disease in non–Native Alaska children younger than 2 years.
Conclusions Alaska Native children are experiencing replacement invasive pneumococcal disease with serotypes not covered by heptavalent pneumococcal conjugate vaccine. The demonstration of replacement invasive pneumococcal disease emphasizes the importance of ongoing surveillance and development of expanded valency vaccines.
Author Affiliations: Arctic Investigations Program, National Center for Preparedness Detection and Control of Infectious Diseases, Centers for Disease Control and Prevention (Drs Singleton, Hennessy, Hammitt, Rudolph, and Parkinson and Mss Bulkow, Zulz, and Hurlburt), Alaska Native Tribal Health Consortium (Drs Singleton and Hammitt), and Alaska Division of Public Health (Dr Butler), Anchorage, Alaska.
RELATED ARTICLE
Invasive Pneumococcal Disease: The Target Is Moving
Timothy R. Peters and Katherine A. Poehling
JAMA. 2007;297(16):1825-1826.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Second Pilus Type in Streptococcus pneumoniae Is Prevalent in Emerging Serotypes and Mediates Adhesion to Host Cells
Bagnoli et al.
J. Bacteriol. 2008;190:5480-5492.
ABSTRACT
| FULL TEXT
Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment
Proc. Natl. Acad. Sci. USA 2008;105:9361-9366.
Pneumococcal Mastoiditis in Children and the Emergence of Multidrug-Resistant Serotype 19A Isolates
Ongkasuwan et al.
Pediatrics 2008;122:34-39.
ABSTRACT
| FULL TEXT
Polyclonal Population Structure of Streptococcus pneumoniae Isolates in Spain Carrying mef and mef plus erm(B)
de la Pedrosa et al.
Antimicrob. Agents Chemother. 2008;52:1964-1969.
ABSTRACT
| FULL TEXT
Streptococcus pneumoniae Surface Protein PcpA Elicits Protection against Lung Infection and Fatal Sepsis
Glover et al.
Infect. Immun. 2008;76:2767-2776.
ABSTRACT
| FULL TEXT
Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades
Darrieux et al.
J Med Microbiol 2008;57:273-278.
ABSTRACT
| FULL TEXT
Pneumococcal Vaccination for Patients With COPD: Current Practice and Future Directions
Schenkein et al.
Chest 2008;133:767-774.
ABSTRACT
| FULL TEXT
Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies
Giefing et al.
J. Exp. Med. 2008;205:117-131.
ABSTRACT
| FULL TEXT
Emergence of Antimicrobial-Resistant Serotype 19A Streptococcus pneumoniae Massachusetts, 2001-2006
JAMA 2007;298:2612-2614.
FULL TEXT
Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7-Valent Conjugate Vaccine as an Otopathogen in Children
Pichichero and Casey
JAMA 2007;298:1772-1778.
ABSTRACT
| FULL TEXT
Antimicrobial Resistance: It's Not Just for Hospitals
Bancroft
JAMA 2007;298:1803-1804.
FULL TEXT
Functional Antibodies to the O-Acetylated Pneumococcal Serotype 15B Capsular Polysaccharide Have Low Cross-Reactivities with Serotype 15C
Rajam et al.
CVI 2007;14:1223-1227.
ABSTRACT
| FULL TEXT
Pneumococcal Vaccine: The Good, the Bad, and the Uncertain
JWatch Pediatrics 2007;2007:1-1.
FULL TEXT
Replacement of Pneumococcal Serotypes After PCV7 Vaccination
JWatch Infect. Diseases 2007;2007:1-1.
FULL TEXT
Invasive Pneumococcal Disease: The Target Is Moving
Peters and Poehling
JAMA 2007;297:1825-1826.
FULL TEXT
|
